Belite Bio completes NDA submission for tinlarebant in Stargardt disease
Belite Bio has completed the rolling submission of its New Drug Application to the US Food and Drug Administration for tinlarebant, an investigational oral therapy for Stargardt disease type 1 (STGD1). The San Diego-based company initiated the rolling NDA in April 2026, and the completed dossier now enters the FDA's standard 60-day filing review. If the agency accepts the application, a PDUFA target action date will be assigned, setting a formal clock on a potential approval decision.
STGD1 is a rare inherited retinal disease caused by mutations in the ABCA4 gene. It affects an estimated 53,000 people in the United States and leads to progressive, irreversible loss of central vision, often beginning in adolescence or early adulthood. There are currently no approved treatments for the condition anywhere in the world, making Belite Bio's submission a significant regulatory milestone for patients and families who have had no pharmacological options.
The science and the trial data
Tinlarebant targets retinol binding protein 4 (RBP4), the sole carrier protein responsible for transporting vitamin A from the liver to the eye. By reducing serum RBP4 levels, the drug limits the supply of retinol entering the eye and thereby slows the formation of bisretinoids, toxic by-products of the visual cycle that accumulate in retinal cells and drive disease progression in STGD1. The mechanism also has potential relevance in geographic atrophy, the advanced form of dry age-related macular degeneration, and Belite Bio is separately running the Phase 3 PHOENIX trial in that indication.
The NDA rests primarily on data from the Phase 3 DRAGON trial in adolescent and adult STGD1 patients, which the company says met its primary endpoint by demonstrating a statistically significant reduction in the growth rate of retinal lesions compared with placebo. Chief Medical Officer Hendrik Scholl said the results "underscore tinlarebant's benefit and pave the way for it to potentially become the first approved therapy for this devastating disease." A follow-on study, DRAGON II, is ongoing in a similar population. Belite Bio holds Breakthrough Therapy Designation, Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation in the US for tinlarebant, as well as Orphan Drug status in Europe, Japan, and Switzerland, and Sakigake Designation in Japan.
Regulatory read-across and competitive context
The Breakthrough Therapy Designation, granted on the basis of high unmet need, entitles Belite Bio to more intensive FDA guidance and rolling review, both of which have already been utilised. The designation does not guarantee approval, but it signals that the agency shares the sponsor's view of the condition's severity and the clinical gap. Investors will focus on whether the FDA accepts the filing within the 60-day window, and subsequently on the PDUFA date, which would set the timeline for a commercial launch the company says it is already preparing for.
The inherited retinal disease space has attracted growing interest from both large pharma and specialist rare-disease developers. Spark Therapeutics' voretigene neparvovec, approved in 2017 for RPE65-associated retinal dystrophy, established the regulatory template for inherited retinal conditions, though it targets a different gene and uses a gene therapy approach rather than a small molecule. For STGD1 specifically, no gene therapy has yet advanced to approval, partly because of the large size of the ABCA4 gene and the technical challenges of AAV-based delivery. Tinlarebant's oral, once-daily profile, if approved, could represent a meaningful commercial differentiator in a patient population that skews younger and for whom tolerability and convenience matter alongside efficacy. Near-term catalysts include formal FDA acceptance of the NDA and the subsequent PDUFA date assignment.